Loading...
Docoh

Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company

CRNX stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 22
18 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 62.79M 62.79M 62.79M 62.79M 62.79M 62.79M
Cash burn (monthly) 27.75M 9.71M 14.35M 11.3M 9.33M 7.51M
Cash used (since last report) 44.92M 15.71M 23.22M 18.28M 15.09M 12.15M
Cash remaining 17.88M 47.08M 39.57M 44.51M 47.7M 50.64M
Runway (months of cash) 0.6 4.9 2.8 3.9 5.1 6.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 22 Jeff E. Knight Common Stock Sell Dispose S No No 20.7004 1,152 23.85K 4,950
13 Jul 22 Fust Matthew K Common Stock Sell Dispose S No No 20.957 5,700 119.45K 12,536
13 Jul 22 Fust Matthew K Common Stock Option exercise Acquire M No Yes 1.45 5,700 8.27K 18,236
13 Jul 22 Fust Matthew K NQSO Common stock Option exercise Dispose M No Yes 1.45 5,700 8.27K 0
17 Jun 22 Nichols Weston Stock Option Common Stock Grant Acquire A No No 18.29 17,500 320.08K 17,500
17 Jun 22 Fust Matthew K Stock Option Common Stock Grant Acquire A No No 18.29 17,500 320.08K 17,500
17 Jun 22 Caren Deardorf Stock Option Common Stock Grant Acquire A No No 18.29 4,375 80.02K 4,375
20 May 22 Jeff E. Knight Common Stock Other Acquire J No No 17.44 1,152 20.09K 6,102
13F holders Current Prev Q Change
Total holders 115 119 -3.4%
Opened positions 14 14
Closed positions 18 16 +12.5%
Increased positions 46 43 +7.0%
Reduced positions 31 38 -18.4%
13F shares Current Prev Q Change
Total value 3.15B 1.1B +186.2%
Total shares 55.4M 50.28M +10.2%
Total puts 0 0
Total calls 133.6K 0 NEW
Total put/call ratio
Largest owners Shares Value Change
Driehaus Capital Management 5.47M $102.1M +10.7%
Perceptive Advisors 5.32M $99.24M +3.1%
BLK Blackrock 3.79M $70.68M +14.9%
BVF 3.68M $68.61M +22.5%
Orbimed Advisors 3.2M $59.62M 0.0%
Biotechnology Value Fund L P 3M $67.8M 0.0%
FMR 2.99M $55.71M -10.5%
Vanguard 2.44M $45.59M +16.4%
Bain Capital Life Sciences Investors 2.31M $43M +13.6%
Wellington Management 1.82M $34.01M +77.2%
Largest transactions Shares Bought/sold Change
Suvretta Capital Management 1.13M +1.13M NEW
Wellington Management 1.82M +794.23K +77.2%
BVF 3.68M +675.07K +22.5%
First Light Asset Management 1.24M +657.84K +112.9%
EcoR1 Capital 1.33M +540.05K +68.3%
Driehaus Capital Management 5.47M +530.45K +10.7%
BLK Blackrock 3.79M +492.7K +14.9%
Deep Track Capital 1.05M -488.72K -31.7%
Versant Venture Management 0 -410.36K EXIT
FMR 2.99M -350.38K -10.5%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: avoid, begun, herewith, implied, Latham, LLP, reassessed, supplement
Removed: assembled, decrease, expansive, file, seasoned, team

Patents

Utility
Somatostatin modulators and uses thereof
16 Aug 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Utility
Formulations of a Somatostatin Modulator
12 May 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Utility
Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof
12 May 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Utility
Formulations of a Somatostatin Modulator
10 Mar 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Utility
Formulations of a somatostatin modulator
8 Mar 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.